MDM2
E3 ubiquitin-protein ligase Mdm2
As of the edition of 20 October 2026, MDM2 (E3 ubiquitin-protein ligase Mdm2, UniProt Q00987) has 14 drugs tested at it and 13 companies on the list, 8 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q00987
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 147
- Disease areas
- Cancer; Blood and lymph; Immune system; Lungs and airways; Digestive system; Skin and connective tissue; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 102
Drugs at this target
| Status | Count |
|---|---|
| Active | 3 |
| Went quiet | 5 |
| Stopped | 5 |
| Status not established | 1 |
| Total | 14 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Navtemadlin | Active | Phase 3 | none listed |
| Idasanutlin | Stopped | Phase 3 | none listed |
| Siremadlin | Stopped | Phase 2 | none listed |
| Milademetan | Stopped | Phase 3 | none listed |
| Brigimadlin | Active | Phase 3 | none listed |
| Alrizomadlin | Active | Phase 2 | none listed |
| RO-5045337 | Went quiet | Phase 1 | none listed |
| MK-8242 | Stopped | Phase 1 | none listed |
| SAR-405838 | Went quiet | Phase 1 | none listed |
| ASTX295 | Stopped | Phase 1 | none listed |
| CGM-097 | Went quiet | Phase 1 | none listed |
| KT-253 | Status not established | Phase 1 | none listed |
12 of 14 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 8 |
| Engaged | 1 |
| Undetermined | 4 |
| Total on the list | 13 |
The other 10 companies at MDM2
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at MDM2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.